{"id":"NCT00979407","sponsor":"GlaxoSmithKline","briefTitle":"Study to Evaluate Immunological Equivalence Between Two Investigational Influenza Vaccines in Adults (H1N1)","officialTitle":"Immunological Equivalence Between GSK2340272A and GSK2340274A Influenza Vaccines in Adults Aged 18 to 60 Years","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-10-12","primaryCompletion":"2009-11-09","completion":"2010-11-04","firstPosted":"2009-09-18","resultsPosted":"2018-08-06","lastUpdate":"2018-08-06"},"enrollment":336,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Influenza"],"interventions":[{"type":"BIOLOGICAL","name":"Influenza vaccine GSK2340272A","otherNames":[]},{"type":"BIOLOGICAL","name":"Influenza vaccine GSK2340274A","otherNames":[]}],"arms":[{"label":"GSK2340272A GROUP","type":"EXPERIMENTAL"},{"label":"GSK2340274A GROUP","type":"EXPERIMENTAL"}],"summary":"The primary purpose of the study is to assess the equivalence of the immune response elicited by two GSK Biologicals' adjuvanted influenza investigational vaccines (GSK2340272A and GSK2340274A) in adults aged 18 to 60 years. The second purpose of the study is to evaluate the safety and reactogenicity of these two vaccines.","primaryOutcome":{"measure":"Titers for Serum Hemagglutination Inhibition (HI) Antibodies Against Flu A/CAL/7/09 Strain of Influenza Disease","timeFrame":"At Day 21","effectByArm":[{"arm":"GSK2340272A GROUP","deltaMin":383.6,"sd":null},{"arm":"GSK2340274A GROUP","deltaMin":339.1,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":10,"exclusionCount":16},"locations":{"siteCount":7,"countries":["France","Germany"]},"refs":{"pmids":["24041010"],"seeAlso":["https://www.clinicalstudydatarequest.com"]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":167},"commonTop":["Pain","Myalgia","Fatigue","Headache","Arthralgia"]}}